SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China

NEXT STORY
Two Top Researchers find Breakthrough Discoveries using Predictive Oncology’s Wholly Owned Subsidiary, TumorGenesis’s Technology
PREV STORY
Avadel Pharmaceuticals Appoints Richard Kim as Chief Commercial Officer to Lead the Commercial Launch of Once-Nightly FT218
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program

New post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients ...

author_avatar
NASDAQ Market News

PetLife Pharmaceuticals Announces the Addition of Dr. Simon Wood PhD as the Company’s new Scientific Officer with plans to expand its Current Portfolio of Veterinarian Drugs and Nutraceuticals

Hancock, MD, Oct. 19, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) ...

author_avatar
NASDAQ Market News

The Global Therapeutic Vaccines Market is expected to grow by $ 3.78 bn during 2020-2024 progressing at a CAGR of 43% during the forecast period

author_avatar
NASDAQ Market News